LENZ Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . LENZ Therapeutics
LENZ Stock   12.77  0.27  2.07%   
LENZ Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing LENZ Therapeutics' valuation are provided below:
Gross Profit
17.5 M
Market Capitalization
403 M
Enterprise Value Revenue
11.5312
Revenue
17.5 M
Earnings Share
(2.06)
We have found one hundred twenty available fundamental ratios for LENZ Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of LENZ Therapeutics last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself for few more years. Market Cap is likely to rise to about 580.6 M in 2026. Enterprise Value is likely to rise to about 562.8 M in 2026
Check LENZ Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LENZ Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 49.6 K, Interest Expense of 48 K or Other Operating Expenses of 42.3 M, as well as many indicators such as Price To Sales Ratio of 6.57, Dividend Yield of 0.4 or PTB Ratio of 2.84. LENZ financial statements analysis is a perfect complement when working with LENZ Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with LENZ Stock
Check out the analysis of LENZ Therapeutics Correlation against competitors.
For more information on how to buy LENZ Stock please use our How to Invest in LENZ Therapeutics guide.

LENZ Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets260 M247.6 M51.8 M
Slightly volatile
Short and Long Term Debt Total833 K1.2 M1.6 M
Slightly volatile
Other Current Liabilities7.3 M5 M4 M
Slightly volatile
Total Current Liabilities13.6 M12 M7 M
Slightly volatile
Cash25.3 M23.2 M11 M
Slightly volatile
Cash And Short Term Investments252.4 M240.4 M50 M
Slightly volatile
Common Stock Shares Outstanding25.7 M24.5 M11 M
Slightly volatile
Liabilities And Stockholders Equity260 M247.6 M51.8 M
Slightly volatile
Total Liabilities12.3 M12.9 M21 M
Slightly volatile
Total Current Assets255.9 M243.7 M50.9 M
Slightly volatile
Short Term Debt602.4 K510.3 K1.4 M
Slightly volatile
Property Plant And Equipment Net2.4 M2.3 M1.4 M
Very volatile
Accounts Payable3.5 M4.9 M1.8 M
Slightly volatile
Non Current Assets Total4.1 M3.9 M1.8 M
Slightly volatile
Non Current Liabilities Total889.3 K936.1 K14.3 M
Slightly volatile
Other Current Assets1.7 M3.3 M1.5 M
Slightly volatile
Other Stockholder Equity421.3 M401.2 M72.5 M
Slightly volatile
Property Plant And Equipment Gross2.5 M2.4 M457.4 K
Slightly volatile
Capital Stock8559004.5 M
Slightly volatile
Net Working Capital243.3 M231.7 M56.9 M
Slightly volatile
Common Stock8559002 K
Slightly volatile
Short Term Investments117.3 M170 M198.4 M
Slightly volatile
Non Current Liabilities Other102.8 K139.2 K78.9 K
Slightly volatile

LENZ Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization49.6 K52.2 K162.1 K
Pretty Stable
Interest Expense48 K36 K63.8 K
Slightly volatile
Other Operating Expenses42.3 M67.4 M20 M
Slightly volatile
Total Operating Expenses42.1 M67.3 M20 M
Slightly volatile
Research Development34.6 M34.3 M18.7 M
Slightly volatile
Cost Of Revenue63.4 K66.7 K765.1 K
Slightly volatile
Selling General Administrative34.8 M33.1 M8.5 M
Slightly volatile
Reconciled Depreciation70 K66.7 K14.2 K
Slightly volatile
Net Interest Income5.9 M9.8 M3.2 M
Slightly volatile
Interest Income5.9 M9.8 M3.2 M
Slightly volatile

LENZ Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow38.4 M40.4 M32.7 M
Slightly volatile
End Period Cash Flow17.3 M18.2 M31.5 M
Pretty Stable
Depreciation49.6 K52.2 K622.7 K
Pretty Stable
Total Cash From Financing Activities160.1 M228.9 M83.4 M
Slightly volatile
Stock Based Compensation7.7 M7.3 M1.5 M
Slightly volatile
Issuance Of Capital Stock59.2 M91.4 M36.3 M
Slightly volatile
Other Cashflows From Investing Activities1.5 M1.7 M1.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.577.398.0654
Slightly volatile
Dividend Yield0.40.450.4907
Slightly volatile
Capex To Depreciation8.19.2810.7402
Slightly volatile
EV To Sales4.214.745.1712
Slightly volatile
Payables Turnover0.01490.01570.2223
Very volatile
Research And Ddevelopement To Revenue1.131.271.3838
Slightly volatile
Capex To Revenue0.350.40.432
Slightly volatile
Cash Per Share9.288.842.7232
Slightly volatile
Days Payables Outstanding25.3 K24.1 K8.9 K
Slightly volatile
Income Quality1.131.070.4556
Slightly volatile
Net Debt To EBITDA0.410.439.4351
Slightly volatile
Current Ratio19.2418.334.8109
Slightly volatile
Capex Per Share0.0240.02530.2151
Very volatile
Revenue Per Share1.531.721.8795
Slightly volatile
Interest Debt Per Share0.09190.07460.182
Slightly volatile
Debt To Assets0.0070.0074216
Slightly volatile
Days Of Payables Outstanding25.3 K24.1 K8.9 K
Slightly volatile
Ebt Per Ebit0.930.982.8557
Slightly volatile
Quick Ratio19.2418.334.8109
Slightly volatile
Net Income Per E B T1.111.151.0405
Slightly volatile
Cash Ratio3.171.741.687
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.161.1459
Slightly volatile
Fixed Asset Turnover43.0148.3952.8148
Slightly volatile
Debt Ratio0.0070.0074216
Slightly volatile
Price Sales Ratio6.577.398.0654
Slightly volatile
Asset Turnover0.260.290.3142
Slightly volatile

LENZ Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap580.6 M552.9 M460.1 M
Pretty Stable
Enterprise Value562.8 M536 M439.4 M
Pretty Stable

LENZ Fundamental Market Drivers

About LENZ Therapeutics Financial Statements

LENZ Therapeutics investors use historical fundamental indicators, such as LENZ Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LENZ Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue66.7 K63.4 K
Research And Ddevelopement To Revenue 1.27  1.13 
Capex To Revenue 0.40  0.35 
Revenue Per Share 1.72  1.53 
Ebit Per Revenue(0.63)(0.66)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for LENZ Stock Analysis

When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY